Investors Target Applied Therapeutics in Class Action Lawsuit
LOS ANGELES, Jan. 6, 2025 /PRNewswire/ — The Schall Law Firm, a national firm focused on shareholder rights, is reminding investors of a class action lawsuit against Applied Therapeutics, Inc. (“Applied Therapeutics” or “the Company”) APLT. The lawsuit alleges violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 created by the U.S. Securities and Exchange Commission.
Who Should Participate
Investors who purchased the Company’s securities from January 3, 2024 to December 2, 2024 (the “Class Period”) are encouraged to get in touch with the firm before February 18, 2025.
If you are a shareholder who has experienced a loss, click here to participate.
Contact Information for Participants
Interested individuals can reach Brian Schall at the Schall Law Firm located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, by calling 310-301-3335. Additionally, inquiries can be sent through the firm’s website at www.schallfirm.com or by emailing [email protected].
Please note that the class has yet to be certified, meaning you are not currently represented by an attorney unless you take action. If no action is taken, you will remain an absent class member.
Allegations Against Applied Therapeutics
According to the Complaint, Applied Therapeutics allegedly made false and misleading statements to the market. The Company reportedly did not follow proper trial protocols and good clinical practices for its drug candidate, govorestat. These missteps raised concerns that the FDA might reject the Company’s trial data when the NDA for rovorestat is submitted. Consequently, statements made by the Company were deemed false and misleading throughout the class period, leading to investor losses when the market learned the truth.
Join the Lawsuit
Investors are encouraged to join the case to recover losses incurred.
The Schall Law Firm represents investors globally and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be viewed as Attorney Advertising in some jurisdictions according to local laws and ethical rules.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
View original content to download multimedia:https://www.prnewswire.com/news-releases/aplt-investors-have-opportunity-to-lead-applied-therapeutics-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302342549.html
SOURCE The Schall Law Firm
Market News and Data brought to you by Benzinga APIs
